Trial · NCT00090493
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
NCT00090493, Phase 2, Phase 3, Completed, University of Arkansas; results first posted 2013-06-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma. Trials, record NCT00090493. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00090493
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
- NCT number
- NCT00090493
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
- First posted
- 2004-08-31
- Last updated
- 2013-06-24
- Results first posted
- 2013-06-24
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Participants Experiencing a Response to the Peptide Vaccines. | 2 week intervals | The peptides are fragments from two proteins MAGE-A3 and NY-ESO-1. There will be a series of 12 peptide vaccinations given as a subcutaneous (beneath the skin) injection (vaccines) at 2 week intervals resulting in an immune response to myeloma. The tumor peptides used in the vaccines are unique to myeloma, and it is not expected that there will be an immune response to normal organs. Myeloma cells must express MAGE-A3 or NY-ESO-1, be severe enough to require chemotherapy and stem cell transplantation and have appropriate HLA tissue type. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Participants Experiencing a Response to the Peptide Vaccines. | 2 week intervals | only 2 were complete per protocol. 2 were withdrawn by physician due to relapse. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Participants Experiencing a Response to the Peptide Vaccines. | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 2 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 4 | |
| Overall Study | COMPLETED | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 2 | |
| Overall Study | NOT COMPLETED | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 2 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | DVT | Vascular disorders | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 3 | 4 | 3 |
| serious | Shingles | Skin and subcutaneous tissue disorders | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 1 | 4 | 1 |
| serious | Staphyloccocal infections | Infections and infestations | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 3 | 4 | 3 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | ||
| Total, other adverse events | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 0 | 4 |
| Total, serious adverse events | MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY | 3 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00090493
GET https://conductscience.org/api/trials/v1/NCT00090493/registered